Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 7—July 2017
Research Letter

Disseminated Mycobacterium genavense Infection in Patient with Adult-Onset Immunodeficiency

Takanori AsakuraComments to Author , Ho Namkoong, Takuro Sakagami, Naoki Hasegawa, Kiyofumi Ohkusu, and Akira NakamuraComments to Author 
Author affiliations: Japan Society for the Promotion of Science, Tokyo, Japan (T. Asakura); Keio University School of Medicine, Tokyo (T. Asakura, H. Namkoong, N. Hasegawa); Eiju General Hospital, Tokyo (H. Namkoong); Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan (T. Sakagami); Tokyo Medical University, Tokyo (K. Ohkusu); Asahi General Hospital, Chiba, Japan (A. Nakamura)

Cite This Article

Abstract

We report a case of disseminated Mycobacterium genavense infection resulting from neutralizing anti–interferon-γ autoantibodies in the patient. We identified M. genavense targeting the hsp65 gene in an aspiration specimen of the lymph node. Adult-onset immunodeficiency caused by neutralizing anti–interferon-γ autoantibodies, in addition to HIV infection, can lead to disseminated nontuberculous mycobacterial infection.

Mycobacterium genavense is a ubiquitous nontuberculous mycobacteria (NTM), first described as a human infection in the 1990s as a primary cause of fatal disseminated infection in HIV-infected patients with low CD4 counts (1). M. genavense also is recognized as an opportunistic pathogen in patients without HIV who have severe immunodeficiency, such as that after solid-organ or hematopoietic stem cell transplantation or immunosuppressive therapy (2,3). The diagnosis of M. genavense infection is clinically challenging because of the difficulties in routinely culturing the organism and the absence of specific symptoms, even in fatal infections. Therefore, diagnosing M. genavense infection in patients without known evidence of immunodeficiency is particularly difficult. We report a previously healthy 66-year-old man with multiple lymphadenopathies in whom disseminated M. genavense infection resulting from the presence of neutralizing anti–interferon-γ (anti–IFN-γ) autoantibodies was diagnosed.

In November 2015, the patient sought care at Asahi General Hospital (Chiba, Japan) for a 2-week history of right-side neck swelling and abdominal pain. His vital signs were within reference ranges. Except for right cervical lymphadenopathy, findings on physical examination were unremarkable. HIV antibodies were undetectable, and CD4/CD8 lymphocyte counts were within reference ranges. No mediastinal or lung involvement was detected on chest computed tomography (CT) scan. Gallium-67 single-photon emission CT/CT revealed high-intensity accumulation of the right cervical and ileocolic lymph nodes (Technical Appendix Figure). Acid-fast bacilli (AFB) staining of the lymph-node aspiration specimen yielded positive results; however, findings on solid media culture and PCR for detecting M. tuberculosis, M. avium, and M. intracellulare were negative. After a 6-week outpatient follow-up, the patient returned with newly developed right axillary lymphadenopathy. An aspiration specimen of the lymph node showed positive AFB staining and was submitted for molecular biologic analysis. M. genavense was identified on amplification and sequencing analysis targeting the hsp65 gene (4). We strongly suspected neutralizing anti–IFN-γ autoantibodies as the cause because the whole blood IFN-γ level with mitogen stimulation was low, as determined using an IFN-γ–releasing assay (QuantiFERON TB 3G; Cellestis, Carnagie, VIC, Australia). A high serum-neutralizing anti–IFN-γ autoantibody titer and inhibited STAT1 (signal transducer and activator of transcription 1) phosphorylation through IFN-γ stimulation in the leukocytes were confirmed, leading to a diagnosis of disseminated M. genavense infection. Clarithromycin, ethambutol, rifampin, and amikacin were administered. Lymphadenopathy improved after 6 weeks, and amikacin was discontinued. No relapse occurred during 16 months of treatment.

Recent studies have described disseminated NTM infection in patients in Asia with adult-onset immunodeficiency resulting from neutralizing anti–IFN-γ autoantibodies (57). Disseminated infection mainly involves the lymph nodes, followed by the osteoarticular system, bone, lungs, and skin (6,7). The pathogen comprises rapidly and slowly growing mycobacteria; M. avium complex and M. abscessus are the most frequently detected. Although the long-term outcome is unclear, most patients need long-term antimicrobial therapy, and some relapses occur after treatment discontinuation (6,7). Adjuvant rituximab therapy has been used for refractory disease (8).

Although disseminated M. genavense infections formerly only were known to occur in HIV-infected patients, the epidemiologic shift to infections in patients without HIV reflects the introduction of combination antiretroviral therapy and increasing use of immunosuppressive agents (2). In 2 previous series comprising 14 HIV-negative patients with M. genavense infection, most patients had known evidence of immunodeficiency; of the 12 patients treated with immunosuppressive agents, 5 had sarcoidosis, 5 were solid-organ transplantation recipients, 1 had non-Hodgkin lymphoma, and 1 had rheumatoid arthritis. Only 2 patients were identified with adult-onset innate immunodeficiency (2,3); 1 patient had innate interleukin-12 receptor deficiency and 1 had idiopathic CD4 lymphocytopenia.

Needle aspirates and tissue biopsy provide higher NTM diagnostic yields than does swab sampling but are insufficiently sensitive. Therefore, less frequently encountered mycobacterial species are identified by gene sequencing, reverse hybridization, and high-performance liquid chromatography (9). Moreover, the identification of M. genavense infection using standard mycobacterial culture methods is difficult. Acidified solid media testing with blood and charcoal is probably the most suitable method (10); however, accurate diagnosis requires additional molecular biologic analysis, such as amplification and sequencing of the 16S ribosomal RNA, hsp65, or rpoB genes. In this case, we identified M. genavense using a direct molecular biologic method for aspiration specimens from the lymph node.

Little is known about death among HIV-negative patients with M. genavense infection, although some patients reportedly have died (2,3). Although their conditions eventually improve, despite a lack of early identification of M. genavense, delayed diagnosis might influence death. Direct molecular biologic methods could better identify M. genavense infection and improve prognosis.

We report a case of disseminated M. genavense infection resulting from neutralizing anti–IFN-γ autoantibodies in the patient. M. genavense infection should be considered in the differential diagnosis of mycobacteria detected with AFB staining but not with culture, even in patients without known evidence of immunodeficiency. Adult-onset immunodeficiency acquired by neutralizing anti–IFN-γ autoantibodies, in addition to HIV infection, can lead to disseminated NTM infection.

Dr. Asakura is a medical doctor in the Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, in Tokyo, Japan. His research interests include nontuberculous mycobacterial infection and non–cystic fibrosis bronchiectasis.

Top

References

  1. Bessesen  MT, Shlay  J, Stone-Venohr  B, Cohn  DL, Reves  RR. Disseminated Mycobacterium genavense infection: clinical and microbiological features and response to therapy. AIDS. 1993;7:135761. DOIPubMed
  2. Hoefsloot  W, van Ingen  J, Peters  EJ, Magis-Escurra  C, Dekhuijzen  PN, Boeree  MJ, et al. Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases. Clin Microbiol Infect. 2013;19:4327. DOIPubMed
  3. Charles  P, Lortholary  O, Dechartres  A, Doustdar  F, Viard  JP, Lecuit  M, et al.; French Mycobacterium genavense Study Group. Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007. Medicine (Baltimore). 2011;90:22330. DOIPubMed
  4. Pai  S, Esen  N, Pan  X, Musser  JM. Routine rapid Mycobacterium species assignment based on species-specific allelic variation in the 65-kilodalton heat shock protein gene (hsp65). Arch Pathol Lab Med. 1997;121:85964.PubMed
  5. Browne  SK, Burbelo  PD, Chetchotisakd  P, Suputtamongkol  Y, Kiertiburanakul  S, Shaw  PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367:72534. DOIPubMed
  6. Chi  CY, Lin  CH, Ho  MW, Ding  JY, Huang  WC, Shih  HP, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore). 2016;95:e3927. DOIPubMed
  7. Valour  F, Perpoint  T, Sénéchal  A, Kong  XF, Bustamante  J, Ferry  T, et al.; Lyon TB study group. Lyon TB Study Group. Interferon-γ autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis. 2016;22:11246. DOIPubMed
  8. Browne  SK, Zaman  R, Sampaio  EP, Jutivorakool  K, Rosen  LB, Ding  L, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012;119:39339. DOIPubMed
  9. Piersimoni  C, Scarparo  C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis. 2009;15:13518, quiz 1544. DOIPubMed
  10. Realini  L, De Ridder  K, Hirschel  B, Portaels  F. Blood and charcoal added to acidified agar media promote the growth of Mycobacterium genavense. Diagn Microbiol Infect Dis. 1999;34:4550. DOIPubMed

Top

Cite This Article

DOI: 10.3201/eid2307.161677

Table of Contents – Volume 23, Number 7—July 2017

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Akira Nakamura, Department of Internal Medicine, Asahi General Hospital, 1326 I, Asahi, Chiba 289-2511, Japan; ; or Takanori Asakura, Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine,, Shinanomachi 35, Shinjuku, Tokyo 160-8582, Japan

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: June 19, 2017
Page updated: June 19, 2017
Page reviewed: June 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external